Literature DB >> 7589032

Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

A Balogh1, G Klinger, L Henschel, A Börner, R Vollanth, W Kuhnz.   

Abstract

In a controlled clinical trial, the elimination of caffeine was examined in 20 healthy women prior to and during one cycle of treatment with either of two oral contraceptive formulations, one containing 0.075 mg gestodene and 0.03 mg ethinylestradiol and one containing 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol. In addition, caffeine clearance was determined 1 month after the last intake of the oral contraceptives. Compared with pretreatment values, the clearance of caffeine was reduced by about 54% and 55% after one treatment cycle with gestodene- and the levonorgestrel-containing oral contraceptive, respectively. Other pharmacokinetic parameters of caffeine, such as tmax and Cmax, were not affected. Clearance values returned to pretreatment values 1 month after the last administration of the oral contraceptives. There was no difference in the reduction of caffeine clearance between contraceptive formulations. A small, but significant difference in the AUC(0-24 h) values of ethinylestradiol was noted between both preparations. There was no correlation between the AUC(model) values of caffeine and the AUC(0-24 h) values of ethinylestradiol. In the present study, a somewhat more pronounced effect on the elimination of caffeine was observed than in previous investigations, where several contraceptive steroids were administered only for a period of 2 weeks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589032     DOI: 10.1007/BF00192743

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids.

Authors:  E C Rietveld; M M Broekman; J J Houben; T K Eskes; J M van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.

Authors:  D J Back; R Houlgrave; J F Tjia; S Ward; M L Orme
Journal:  J Steroid Biochem Mol Biol       Date:  1991-02       Impact factor: 4.292

Review 3.  Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs.

Authors:  F P Guengerich
Journal:  Am J Obstet Gynecol       Date:  1990-12       Impact factor: 8.661

4.  Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.

Authors:  J Hammerstein; E Daume; A Simon; U H Winkler; A E Schindler; D J Back; S Ward; A Neiss
Journal:  Contraception       Date:  1993-03       Impact factor: 3.375

5.  Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae.

Authors:  H P Eugster; M Probst; F E Würgler; C Sengstag
Journal:  Drug Metab Dispos       Date:  1993 Jan-Feb       Impact factor: 3.922

6.  Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay.

Authors:  W Kuhnz; T Louton; D J Back; K Michaelis
Journal:  Arzneimittelforschung       Date:  1993-01

7.  Intra-individual variability of caffeine elimination in healthy subjects.

Authors:  A Balogh; S Harder; R Vollandt; A H Staib
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-10

8.  Inhibition of hepatic demethylation of aminopyrine by oral contraceptive steroids in humans.

Authors:  R Herz; H R Koelz; U P Haemmerli; I Benes; A L Blum
Journal:  Eur J Clin Invest       Date:  1978-02       Impact factor: 4.686

9.  Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives.

Authors:  C Jung-Hoffmann; H Kuhl
Journal:  Contraception       Date:  1989-09       Impact factor: 3.375

10.  Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.

Authors:  W Kuhnz; D Back; J Power; B Schütt; T Louton
Journal:  Horm Res       Date:  1991
View more
  16 in total

Review 1.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

3.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Authors:  K Laine; M Anttila; A Helminen; H Karnani; R Huupponen
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 4.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

6.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 7.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 8.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects.

Authors:  Sanna Palovaara; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

10.  Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination.

Authors:  H Jeong; S Choi; J W Song; H Chen; J H Fischer
Journal:  Xenobiotica       Date:  2008-01       Impact factor: 1.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.